Latest Breaking News On - Renal cell cancer - Page 6 : comparemela.com

ASCO GU 2023: Patient and Physician Preferences for Adjuvant Treatment of Renal Cell Carcinoma: A Discrete-Choice Experiment

ASCO GU 2023: Patient and Physician Preferences for Adjuvant Treatment of Renal Cell Carcinoma: A Discrete-Choice Experiment
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoShawna calhounChristopher jd wallisShawnar calhounMerck co incUniversity of torontoGenitourinary gu american society of clinical oncologyAmerican society for clinical oncologyAmerican societyClinical oncologyGenitourinary cancer symposiumPoster sessionRenal cell cancerAnnual meeting

New Cancer Screen, Same Issues: Physicians Confront Galleri Test

A cancer screening program in Arizona that offers the Galleri blood test to first responders provides some insight into how well the test can catch cancers in this high-risk group.

United statesElectra paskettAparna parikhAnthony arenzVershalee shuklaJi hyun leeWhitney jonesMike curtisDivision of quantitative sciencesCancer center hospitalOhio state university in columbusUniversity of florida health cancer centerDrug administrationUniversity of floridaVincere cancer centerGrail bio

Merck: New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

Not intended for UK-based media Long-term follow-up of the Phase III JAVELIN Bladder 100 study demonstrated median overall survival from start of chemotherapy of 29.7 months among patients receiving

United statesSrikala sridharAmerican society of clinical oncologyMerck pressEuropean commissionDrug administrationPrincess margaret cancer centreMerck kgaMerck kgaaAmerican cancer societyUnited kingdom basedClinical oncologyGenitourinary cancers symposiumSenior vice president headMedical unit oncologySession details

New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial.

United statesSrikala sridharAmerican society of clinical oncologyMerck pressEuropean commissionDrug administrationPrincess margaret cancer centreMerck kgaMerck kgaaAmerican cancer societyUnited kingdom basedClinical oncologyGenitourinary cancers symposiumSenior vice presidentMedical unit oncologySession details

Ipsen Pharma: Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma

Three-year data - with a median follow-up of 44 months - from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib regardless

France generalUnited statesUnited kingdomDennis riedlBradley mcgregorMauricio burottoAntoine thiery vuilleminLaurence albigesPhilippe barthIpsen euronextPaul nathanTonik choueiriAnand sharmaBradford hill clinical research centerTakeda pharmaceutical companyEuropean union